Is a P40-Negative Result Good or Bad?

A p40-negative result is not inherently good or bad. It is a diagnostic clue, not a verdict. p40 is a protein marker that pathologists use to identify squamous cell carcinomas, so when a tumor stains negative for p40, it generally means the tumor is not squamous in origin. What that means for you depends entirely on the clinical context: which organ the biopsy came from, what other markers were tested alongside it, and what your doctors suspected in the first place. The answer shifts depending on whether we’re talking about a lung biopsy, a breast lesion, a bladder tumor, or something else entirely.

What p40 Is and Why Pathologists Use It

p40 is a protein found in the nuclei of squamous epithelial cells, the flat, scale-like cells that line surfaces such as the skin, mouth, esophagus, and airways. When a pathologist takes a tissue sample from a suspected tumor and needs to determine whether it is a squamous cell carcinoma, they stain the tissue with an antibody that binds to p40. If the tumor cells light up with strong, widespread nuclear staining, that strongly supports a squamous cell carcinoma diagnosis. If the cells stay dark, it suggests the tumor is something else.

This matters because different cancer types require different treatments. In the lungs, for instance, squamous cell carcinoma and adenocarcinoma are treated with different drug regimens. Misclassifying one as the other can lead to ineffective therapy or dangerous side effects. p40 emerged as a favored marker because it is highly specific for squamous differentiation, meaning it rarely stains positive in non-squamous tumors. An older, closely related marker called p63 does the same job but with a significant drawback: it also lights up in a substantial fraction of adenocarcinomas and even some lymphomas, which can lead to misdiagnosis.¹

Lung Cancer and the Most Common Scenario

The place where a p40 result comes up most often is in lung cancer diagnosis. Non-small cell lung cancer, which accounts for the vast majority of lung cancers, is broadly divided into squamous cell carcinoma and adenocarcinoma. The distinction drives treatment: certain targeted therapies and immunotherapy regimens work better in one subtype than the other. But under the microscope, especially on a small biopsy or needle aspirate, these two subtypes can look frustratingly similar. That’s where immunohistochemistry panels come in.

In this context, a p40-negative result generally points away from squamous cell carcinoma and toward adenocarcinoma. Studies consistently show that p40 stains positive in the vast majority of lung squamous cell carcinomas while staying negative in essentially all adenocarcinomas. One study found p40 expression in about 77% of lung squamous cell carcinomas while every single adenocarcinoma tested was p40-negative, giving p40 a specificity of 100% for squamous cell carcinoma in that sample.² Another study reported p40 sensitivity of 100% for squamous cell carcinoma and specificity of 98%, with only about 3% of adenocarcinomas showing any p40 staining at all.¹

So if your lung biopsy came back p40-negative, it doesn’t mean the news is good or bad in a simple sense. It means the pathologist is now looking at other markers to confirm whether the tumor is an adenocarcinoma, a neuroendocrine tumor, or something less common. Adenocarcinoma is the most common subtype of lung cancer overall, and many targeted therapies exist for it. Getting the classification right is what matters.

Why p40 Replaced p63 in Many Labs

Before p40 became widely adopted, most pathology labs relied on p63 as their go-to squamous marker. The two proteins are closely related: p40 is actually a truncated version of p63, specifically the ΔNp63 isoform. The critical difference is in how cleanly they separate squamous tumors from everything else.

p63 is sensitive for squamous cell carcinoma, catching virtually all of them, but it also stains positive in roughly a third of adenocarcinomas and over half of large cell lymphomas.¹ That overlap creates a real danger: a pathologist seeing p63 positivity in what is actually an adenocarcinoma might call it squamous, sending the patient down the wrong treatment path. p40 largely eliminates that problem. When it does show up in an adenocarcinoma, the staining is typically very faint and limited to isolated cells, easily distinguishable from the strong, diffuse pattern seen in true squamous tumors.³

This is why many labs have shifted to using p40 as their primary squamous marker, and why a negative p40 result carries more diagnostic weight than a negative p63 result would. If p40 says a lung tumor is not squamous, that conclusion is very reliable.

A p40-Negative Result Never Stands Alone

Pathologists almost never make a diagnosis based on a single marker. p40 is part of a panel, and the other members of that panel determine what a negative p40 result actually means. In lung cancer workups, the two most common companions are TTF-1 (thyroid transcription factor 1) and napsin A, both of which are markers for adenocarcinoma. If p40 is negative while TTF-1 and napsin A are positive, the diagnosis of lung adenocarcinoma becomes very confident.⁴

A triple-marker approach combining TTF-1, napsin A, and p40 has been validated on both surgical specimens and tiny needle biopsies. In one study, the combination achieved 100% sensitivity and about 97% specificity for squamous cell carcinoma, and 86% sensitivity and 100% specificity for adenocarcinoma.⁵ This panel approach is especially valuable because modern lung cancer treatment increasingly depends on molecular testing for specific mutations, and that molecular testing requires preserved tumor tissue. Using a small, efficient marker panel means pathologists can get a definitive classification while saving enough tissue for genetic analysis.

The practical impact of these panels is striking. In one Indian study, eight cases initially diagnosed as squamous cell carcinoma on morphology alone turned out to be p40-negative and TTF-1/napsin A-positive. They were reclassified as adenocarcinoma, which changed the entire treatment plan for those patients.⁶

What Happens When Both p40 and TTF-1 Are Positive

There is a less common but clinically interesting scenario where a tumor expresses both p40 and TTF-1 at the same time. In standard diagnostic logic, these two markers are supposed to be mutually exclusive: p40 flags squamous, TTF-1 flags adenocarcinoma. When both light up, the pathologist is looking at something unusual.

A recent study analyzing this co-expression pattern found it in about 19% of non-small cell lung cancer cases examined. These dual-positive tumors tended to show solid growth patterns and were significantly more likely to carry TP53 mutations and abnormalities in the FGFR signaling pathway. Interestingly, co-expression did not appear to affect overall survival compared to tumors expressing only one marker.⁷ This is an evolving area of research, but it illustrates that p40 results exist on a spectrum. A weakly positive or focally positive p40 result raises different questions than a strongly positive or completely negative one.

p40 in Cancers Outside the Lungs

Although lung cancer is where p40 gets the most attention, the marker is used across several organ systems. The interpretation of a p40-negative result shifts depending on where the tumor was found.

Bladder and Urinary Tract

In urothelial carcinoma (bladder cancer), p40 is actually expected to be positive in most cases, because urothelial cells share some squamous characteristics. One study found p40 sensitivity of about 85% for invasive urothelial carcinoma, comparable to the widely used markers GATA3 and p63. When p40, GATA3, and uroplakin II were combined, they identified over 94% of invasive urothelial carcinomas, including more than 92% of high-grade cases.⁸ Here, a p40-negative result might push the pathologist to consider whether the tumor originated somewhere other than the bladder, such as a metastasis from a different organ.

Head and Neck

The head and neck region presents a particular challenge because many different tumor types can arise in a small anatomic space, especially in the sinuses. p40 helps sort through these. In sinonasal undifferentiated carcinoma (SNUC), a rare and aggressive tumor, p40 negativity is actually a useful diagnostic finding. One study concluded that p40 negativity, along with absence of cytokeratin 5/6, helps establish the diagnosis of SNUC with reasonable accuracy.⁹

The picture is muddied by the fact that some non-squamous sinonasal tumors can show focal p40 staining. Esthesioneuroblastomas, NUT midline carcinomas, and adenoid cystic carcinomas have all been reported to express p40 in a subset of cases, though the staining tends to be patchy and weak rather than the strong, diffuse pattern seen in true squamous tumors.¹⁰ A completely p40-negative result in the sinonasal region meaningfully narrows the diagnostic possibilities.

Breast

In breast pathology, p40 plays a different role entirely. Rather than identifying cancer type, it helps determine whether myoepithelial cells are present. Myoepithelial cells form a layer around normal breast ducts, and their presence or absence is a key factor in distinguishing benign or in-situ disease from invasive carcinoma. p40 stains myoepithelial cells, so the pathologist is looking for p40 positivity around the edges of glandular structures, not within the tumor cells themselves. One study found p40 sensitivity of 99% for detecting myoepithelial cells, though it noted that some cancer cells can also pick up the stain, which means the result needs to be interpreted carefully.¹¹ In this context, a p40-negative result around a suspicious cluster of cells might suggest the myoepithelial layer has been lost, which is a hallmark of invasion.

Cervix

Cervical cancer also divides into squamous cell carcinoma and adenocarcinoma, and the treatment implications differ. p40 shows good performance here, with one study reporting sensitivity of about 85% and specificity of about 97% for distinguishing squamous from glandular cervical tumors. Combining p40 negativity with positivity for the mucin marker MUC5AC yielded nearly 98% specificity for identifying adenocarcinoma.¹²

When a p40-Negative Result Might Be Misleading

No marker is perfect, and there are situations where a p40-negative result could lead a pathologist astray if taken at face value.

The most significant limitation is that p40 can be negative in a genuine squamous cell carcinoma. This happens most often in well-differentiated tumors. One study of fine needle aspirates found that p40 was strongly positive in all moderately and poorly differentiated squamous cell carcinomas but negative or barely reactive in well-differentiated ones. Paradoxically, the tumors that look most obviously squamous under the microscope are the least likely to need the marker, while the ambiguous-looking ones tend to stain strongly.

Small cell lung carcinoma is another situation where p40 negativity is expected and diagnostically useful. All 34 small cell carcinomas in one study were completely negative for p40, helping to separate them from non-small cell tumors on small biopsy samples.¹³ Here, a p40-negative result helps confirm a diagnosis of small cell carcinoma rather than suggesting adenocarcinoma.

Poorly differentiated carcinomas of unknown origin represent a trickier scenario. When the pathologist cannot tell where a metastatic tumor originally came from, p40 negativity rules out squamous differentiation but doesn’t point firmly toward any single alternative. In one series of poorly differentiated carcinomas, none showed p40 or p63 staining, leaving the pathologist to rely on other markers and clinical history.¹⁴

Technical Factors That Can Affect the Result

The reliability of any immunohistochemistry test depends on how it’s performed. With p40, one source of variability is the specific antibody clone the lab uses. The two most common are a rabbit polyclonal antibody and a mouse monoclonal clone called BC28. One study noted that the polyclonal version can stain alveolar macrophages and produce nonspecific background staining in the cytoplasm, which can slightly reduce specificity. The monoclonal clone tends to produce cleaner, purely nuclear staining with less background noise.¹⁵

Other technical variables include tissue fixation time, the thickness of the tissue section, and the antigen retrieval method the lab uses to unmask the protein before staining. These aren’t things patients can control, but they’re worth knowing about if a result seems inconsistent with other findings. In equivocal cases, pathologists may repeat the stain, try a different antibody clone, or request additional tissue.

How Skin Cancer Workups Use p40 Differently

In dermatopathology, squamous cell carcinoma of the skin is usually straightforward to diagnose by appearance alone. p40 becomes relevant when the tumor is poorly differentiated or has an unusual spindle-cell morphology that makes it hard to distinguish from melanoma or other skin cancers. In head and neck spindle cell carcinomas, both p40 and p63 show 100% specificity, though high-grade tumors are more likely to lose staining, and when they do stain, p40 tends to mark a higher percentage of tumor cells than p63 does.¹⁶

A p40-negative result in a spindle-cell skin tumor pushes the pathologist to investigate melanoma, sarcoma, or other non-squamous possibilities. Additional markers like S100 and SOX10, which are positive in melanoma but negative in squamous cell carcinoma, become critical at that stage.¹⁷ In this setting, a p40-negative result is neither reassuring nor alarming on its own. It simply redirects the diagnostic investigation.

What to Ask Your Doctor

If you’ve received a pathology report that mentions p40, a few questions can help you understand what it means in your situation. First, ask what the full immunohistochemistry panel showed, because p40 rarely tells the whole story by itself. Second, ask whether the result was strongly or weakly positive, or completely negative, since intensity and distribution matter. A faint blush in a few scattered cells means something very different from uniform, strong staining across the entire tumor. Third, ask how the p40 result influenced the final diagnosis and, critically, whether it changes the treatment plan.

Patients sometimes worry that any “negative” result on a medical test must be bad news. With p40, the word “negative” is purely descriptive: the protein was not detected in the tissue. It rules things out rather than ruling things in. In a lung biopsy, p40 negativity helps confirm you don’t have squamous cell carcinoma, which may actually open the door to targeted therapies available for adenocarcinoma. In a breast biopsy, the interpretation hinges on where the staining is absent. Context is everything, and the pathologist’s integrative read of all the markers together is far more informative than any single line on the report.